ESR1 and breast carcinoma: In contrast, the NEO-ORB trial showed no improvement in the overall response rate (ORR) and pathologic complete response (pCR) with the addition of alpelisib to letrozole in the neoadjuvant setting of either PIK3CA-mutated or wild-type ER+ early breast cancer [37].